The latest market report published by Credence Research, Inc. “Global Diagnostic Testing for STD’s Market By Type (Syphilis Testing, Gonorrhea Testing, Chlamydia Testing, Herpes Simplex Virus Testing, Human Immunodeficiency Virus Testing, Human Papilloma Virus Testing, Others), By Location (Laboratory Testing, Point Of Care Testing) – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” Global diagnostic testing for STD market is expected to reach US$ 19,716.9 million in 2017 and is expected to reach US$ 42,329.1 million by 2026, increasing to CAGR by 8.9 per cent from 2018 to 2026.
According to statistics supplied by the World Health Organization (WHO), there are roughly 357 million fresh instances of 1 in 4 sexually transmitted diseases of gonorrhea, syphilis, chlamydia and trichomoniasis every year. More than 30 different types of pathogens are reported to be sexually transmitted, of which only bacterial infections are curable. Viral infections are incurable with symptomatic relief only through effective treatment protocols. Rising incidence of resistance to antibiotics results in a high demand for early detection of sexually transmitted diseases.
Browse the full report at https://www.credenceresearch.com/report/diagnostic-testing-for-stds-market
Currently, chlamydia and syphilis together are leading the diagnostic test segment for the STD market. The main variables responsible for their dominance are increased indulgence of unsafe sex with various partners around the globe and increased sexual contact with anal and oral areas. HIV infection testing is experiencing remarkable development owing to the accessibility of extremely sensitive and efficient molecular diagnostic kits for PCR and ELISA methods. Increased lobbying by government and non-governmental organizations resulting in early HIV infection screening.
In the current laboratory test scenario, the location segment for diagnostic testing for STD market is underway. The main parameters accountable for its outstanding development are the availability of qualified workers and the establishment of fresh diagnostic laboratories owing to economic pumping by public health organizations. Point of care testing will record a enormous increase during the forecast period due to the accessibility of the recent molecular diagnostic kits with enhanced ergonomic design, portability and fast turnaround time associated with the diagnosis.
According to Center for Disease Control and Prevention (CDC) in 2017, approximately 2.3 million people are suffering with sexually transmitted disease in the United States. Factors responsible for the dominance of North America are existence of well-developed healthcare infrastructure and domicile of key players. In Europe the market growth is determined by the supportive regulatory environment provided by European Medical Agency favoring the growth of STD’s diagnostic kits. There has been rampant increase in the spread of STD’s throughout the European Union region on account of the recent refugee influx from the Levant region. Asia Pacific is set to register impressive growth during the forecast period on account of rising prevalence of sexually transmitted disease and proactive government initiative in establishing diagnostic centers to curb the spread and fatality of STD’s.
Archrivals competing in the diagnostic testing for STD’s market are Abbott Laboratories, Inc., Bio-Rad Laboratories, Inc., bioMerieux, Danaher Corporation, Diasorin S.p.A, F.Hoffman La-Roche Ltd., Hologic, Inc., MedMira, Inc., Qiagen, Inc., and Siemens Healthcare AG.
Key Market Movements:
- Rising incidence rate of sexually transmitted disease throughout the globe
- Technological adevanmcent in the molecular diagnostic testing kits used for screening of sexually transmitted diseases
- Supportive regulatory scenario favoring market growth and increasing public health awareness resulting in early screening
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/59440
Report Scope by Segments
By Type (2016–2026; US$ Mn)
- Syphilis Testing
- Gonorrhea Testing
- Chlamydia Testing
- Herpes Simplex Virus Testing
- Human Immunodeficiency Virus Testing
- Human Papilloma Virus Testing
By Location (2016–2026; US$ Mn)
- Laboratory Testing
- Point of Care Testing
By Geography Segment (2016–2026; US$ Mn)
- North America
- Asia Pacific (APAC)
- Middle East & Africa (MEA)
- Latin America